Authors
Latest:
SKCC’s Dr. Edith Mitchell Named Enterprise Vice President for Cancer DisparitiesEdith P. Mitchell, MD, MACP, FCCP, FRCP, Director of the Center to Eliminate Cancer Disparities and Clinical Professor of Medicine and Medical Oncology, has been named Enterprise Vice President for Cancer Disparities at Jefferson Health’s Sidney Kimmel Cancer Center.
Latest:
Dr. Spaggiari on Surgical Strategies to Improve Liver Remnants in CRC With Liver MetastasesMario Spaggiari, MD, discusses surgical strategies to improve liver remnants in colorectal cancer with liver metastases.
Latest:
Liso-Cel Proves Active Across High-Risk MCL SubgroupsLiso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features.
Latest:
Dr Li on the Rationale for Evaluating CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBCRoger Li, MD, expands on the mechanism of action for the combination of CG0070 and pembrolizumab, and discusses the rationale for investigating the regimen's synergy in patients with non–muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin.
Latest:
Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical CancerJyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.
Latest:
Closing Expert Perspectives on Treatment in Advanced NSCLCLung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.
Latest:
KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCCFocusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.
Latest:
Dr. Hadaschik on Treatment After Apalutamide Progression in SPARTAN TrialBoris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.
Latest:
Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup AnalysisExpert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.
Latest:
Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual AnemiaRegis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.
Latest:
Future Directions in Chronic GvHDDr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.
Latest:
Dr Sekeres on the Impact of BTK Inhibitors on Approaches to CLL ManagementMikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.
Latest:
Dr. Spitalnik on Goals for the Hemanext® Blood Storage System in Hematologic MalignanciesSteven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies.
Latest:
Improving outcomes in metastatic pancreatic cancerPancreatic cancer remains elusive with extremely low survival rates. Through better utilization of existing therapies and identifying patient subgroups, some believe we are incrementally improving patient outcomes and making more significant advances in care.
Latest:
Dr Chen on the Investigation of CDK4/6 Inhibitors in Early-Stage Breast CancerNan Chen, MD, discusses the investigation of CDK4/6 inhibitors in early-stage breast cancer.
Latest:
Dr Simon on the Utility of Novel Treatments in Diverse Patient Populations With CancerGeorge Simon, MD, FACP, FCCP, discusses the importance of enrolling diverse patient populations in cancer clinical trials.
Latest:
Dr. Polak on Evaluation of Cancer Genomes in Ghana Utilizing Liquid BiopsiesPaz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.
Latest:
Future Perspectives in the Treatment of NeuroblastomaGiselle Sholler, MD, and Anurag Agrawal, MD, close their discussion with a look at the future of neuroblastoma treatment, highlighting research being done in areas such as immunotherapies, CAR T-cell therapy, and genomics for more targeted approaches aiming to enhance patient outcomes.
Latest:
Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS AnalysisExpert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.
Latest:
Dr. Doroshow on Increasing Patient Accrual to Clinical Trials During the COVID-19 PandemicJames H. Doroshow, MD, discusses strategies that were implemented to increase patient accrual to clinical trials during the COVID-19 pandemic.
Latest:
Dr. Maura on the Challenges of Whole-Genome Sequencing in Multiple MyelomaFrancesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.
Latest:
Dr. Force on the Efficacy of Trastuzumab Deruxtecan in the DESTINY-Breast02 Trial for HER2+ Breast CancerJeremy Force, DO, discusses the efficacy of trastuzumab deruxtecan in pretreated patients with HER2-positive breast cancer on the phase 3 DESTINY-Breast02 trial.
Latest:
Dr Zeybek on the Investigation of Neoadjuvant Olaparib in Newly Diagnosed BRCA-Mutant Ovarian CancerBurak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.
Latest:
Surgical Intervention Provides the Foundation for Exploring Immunotherapy in GlioblastomaBecause the current standard-of-care modalities have significant limitations, there has been a great interest in pursuing immunotherapeutic strategies for glioblastoma.
Latest:
Advancements in Targeted Therapy for Metastatic NSCLCShared insight into the transformative impact of targeted therapies in lung cancer treatment, from adjuvant therapy breakthroughs to emerging trials, emphasizing the critical role of comprehensive molecular testing.
Latest:
Therapeutic Frontiers Expand for Patients With Relapsed/Refractory Multiple MyelomaVarious immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.
Latest:
The Medical AI RevolutionWe consider artificial intelligence hype vs reality, focusing on predictive modeling to answer medical questions about diagnosis, treatment choice, etc.
Latest:
Dr Bartsch on the TUXEDO-1 Trial of T-DXd in HER2+ Breast Cancer With Brain MetastasesRupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.
